

ORGANIZED BY

IN AFFILIATION WITH



2<sup>nd</sup> Department of Obstetrics and Gynecology  
Medical School, Aristotle University of Thessaloniki  
Hippokration General Hospital, Thessaloniki, Greece  
Head of Department: **Associate Professor Konstantinos D. Dinas**



Institute of Gynecologic Oncology & Senology  
Thessaloniki, Greece



Institut Bergonie, Bordeaux, France

# GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

Endorsed by **ESGO**



[WEBINAR] 

**Saturday, 27<sup>th</sup> March 2021**

Live Stream - Registration: [www.voyagertravel.gr](http://www.voyagertravel.gr)



**WEBINAR SECRETARIAT**



Vas. Irakleiou 26, 546 24, Thessaloniki, GR

T: +302310250401, F: +302310250418

E: [congress-secretary@voyagertravel.gr](mailto:congress-secretary@voyagertravel.gr) , [www.voyagertravel.gr](http://www.voyagertravel.gr)



# Mefoxil®

cefoxitin sodium

1g/vial

2g/vial

## Διαχρονική αξία

**1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** MEFOXIL **2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ** Κάθε φιαλίδιο περιέχει cefoxitin sodium 1,051g που ισοδυναμεί με cefoxitin 1g. Κάθε φιαλίδιο περιέχει cefoxitin sodium 2,104g που ισοδυναμεί με cefoxitin 2g. **3. ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Κόνις για ενέσιμο διάλυμα. **7. ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** BIANEX A.E - Οδός Τατσοίου, 146 71 Νέα Ερυθραία - Τηλ. 210 8009111-120 10. ΗΜΕΡΟΜΗΝΙΑ ΤΗΣ (ΜΕΡΙΚΗΣ) ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ: 08-11-2018

MEFOXIL 1g/vial N.T 3,77€, Λ.Τ 5,97€. 2g/vial N.T 5,51€, Λ.Τ 8,74€

Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως

Τρόπος Διάθεσης: Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή



**BIANEX A.E.**  
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ  
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEX A.E. - Έδρα : οδός Τατσοίου, 18<sup>ο</sup> χλμ. Ε.Ο. Αθηνών – Λαμίας  
146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία  
Τηλ. : 210 8009111 • Fax: 210 8071573 • E-mail: mailbox@vianex.gr • WEBSITE: www.vianex.gr  
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδήμου 113, 562 24 Εύοσμος Θεσσαλονίκης, Τηλ.: 2310 861683

ΑΡ. Γ.Ε.ΜΗ. 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

# CONTENTS

GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

|                                 |       |
|---------------------------------|-------|
| WELCOME MSG .....               | 05    |
| ORGANIZATION – COMMITTEES ..... | 06    |
| GENERAL INFORMATION .....       | 07    |
| SPEAKERS .....                  | 08    |
| PROGRAM.....                    | 09-11 |
| INDEX.....                      | 12    |
| SPONSORS.....                   | 13    |
| NOTES.....                      | 14-15 |

**Ivor**<sup>®</sup>  
Bemiparin sodium

**IvORMAX**<sup>®</sup>  
Bemiparin sodium

**ΣΥΝΟΠΤΙΚΗ ΠΕΡΙΓΡΑΦΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ**

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 2.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 2.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 12.500 IU (anti Factor Xa) ανά ml ενέσιμο διάλυμα). Η δραστηκότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηκότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόγων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 2.500 IU anti-Xa/0,2 ml BT x 10 PFSYR A.T.: 22,25 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivor 3.500 IU anti-Xa/0,2 ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 3.500 IU (anti Factor Xa\*) ανά 0,2 ml προγεμισμένη σύριγγα (ισοδύναμη με 17.500 IU (anti Factor Xa) ανά ml ενέσιμο διάλυμα). Η δραστηκότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηκότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόγων, βλ. παράγραφο 6.1. **ΣΥΣΚΕΥΑΣΙΕΣ/ΤΙΜΕΣ:** IVOR 3.500 IU anti-Xa/0,2 ml BT x 2 PFSYR A.T.: 10,74 € BT x 10 PFSYR A.T.: 36,05 € BT x 30 PFSYR A.T.: 120,83 €

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** Ivormax 25.000 IU anti-Xa/ml ενέσιμο διάλυμα σε προγεμισμένες σύριγγες **ΠΟΙΟΤΙΚΗ & ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Bemiparin sodium: 25.000 IU (anti-Factor Xa) ανά ml ενέσιμο διάλυμα. Ισοδύναμη με: 5.000 IU (anti-Factor Xa) ανά 0,2 ml προγεμισμένη σύριγγα, 7.500 IU (anti-Factor Xa) ανά 0,3 ml προγεμισμένη σύριγγα, 10.000 IU (anti-Factor Xa) ανά 0,4 ml προγεμισμένη σύριγγα. \* Η δραστηκότητα περιγράφεται σε Διεθνείς μονάδες anti-Factor Xa δραστηκότητας (IU) με βάση το Πρώτο Διεθνές Πρότυπο Αναφοράς Ηπαρίνης Χαμηλού Μοριακού Βάρους. Για τον πλήρη κατάλογο των εκδόγων, βλ. παράγραφο 6.1. **Συσκευασίες/Τιμές:** IVORMAX 25.000 IU anti-Xa/ml, 5.000 IU anti-Xa/0,2 ml BTx2 PFSYR A.T.: 21,86€, 7.500 IU anti-Xa/0,2 ml BTx2 PFSYR A.T.: 19,08€, 10.000 IU anti-Xa/0,2 ml BTx2 PFSYR A.T.: 23,33€

**ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Ενέσιμο διάλυμα σε προγεμισμένες σύριγγες. (Άχρωμο ή ελαφρώς κτρινωπό, διαγυή διαλύμα, ελεύθερο ορατών σωματιδίων). **ΚΑΤΟΧΟΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** BIANEE Α.Ε. – Οδός Τατσιού, 146 71 Νέα Ερυθραία, Τηλ. 210 8009111. **ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 16-12-2016

**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:** Φαρμακευτικό προϊόν για το οποίο απαιτείται ιατρική συνταγή.

Περαιτέρω πληροφορίες διατίθενται από τον ΚΑΚ κατόπιν αιτήσεως.



**BIANEE** Α.Ε.  
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ  
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ

BIANEE Α.Ε. – Έδρα : οδός Τατσιού, 18<sup>ο</sup> χλμ. Ε.Ο. Αθηνών – Λαμίας 146 71 Ν. Ερυθραία Αττικής, Ταχ. Θυρίδα 52894, 146 10 Ν. Ερυθραία  
Τηλ. : 210 8009111 • Fax: 210 8071573 • E-mail: [mailbox@vianex.gr](mailto:mailbox@vianex.gr) • WEBSITE: [www.vianex.gr](http://www.vianex.gr)  
ΘΕΣΣΑΛΟΝΙΚΗ: Ακαδήμου 113, 562 24 Εύσμος Θεσσαλονίκης Τηλ.: 2310 861683

**ΑΡ. Γ.Ε.ΜΗ.** 000274201000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



# WELCOME MESSAGE

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

Dear Colleagues,

the COVID-19 pandemic has been the current dramatic reality for over a year. This situation has not only caused significant mortality and morbidity due to SARS-CoV-2 itself but has also compromised the level of almost all other health medical services. In this context, the treatment of the Gynaecologic Oncology patients has also encountered significant difficulties, often necessitating adaptations to the standard treatment protocols.

This webinar is the first that is organized by our Department as ESGO-certified center, and is designated to discuss the treatment of the Gynaecologic Oncology patients in the context of COVID-pandemic. Specifically, it sets in the center of interest both necessary alterations often needed to be established because of COVID-pandemic, as well as, the reconsideration of all aspects of treatment in the current situation. It is addressed not only to Gynaecologic Oncologists but also to all relative medical specialties, such as Medical Oncologists, Radiotherapists, Pathologists, Radiologists as well as other medical and paramedical professionals enrolled in the treatment of the Gynaecologic Oncology patient.

We would exceptionally like to thank the European Society of Gynaecologic Oncology (ESGO) for the privilege to endorse our webinar. We cordially invite all you to join for free our webinar and therefore contribute to our continuous effort to advance treatment of the Gynaecologic Oncology patients.

**Konstantinos D. Dinas**  
Associate Professor of  
Obstetrics and  
Gynecology  
Head of the 2nd  
Department of Obstetrics  
and Gynecology  
Hippokration General  
Hospital, Greece

**Alexios Papanikolaou**  
Professor of Obstetrics  
and Gynecology  
2nd Department of  
Obstetrics and  
Gynecology  
Hippokration General  
Hospital, Greece

**Stamatios Petousis**  
Obstetrician –  
Gynaecologist  
Academic Fellow, 2nd  
Department of Obstetrics  
and Gynecology  
Hippokration General  
Hospital, Greece

**Dr. Frederic Guyon**  
President of SFOG  
Head of Gynaecologic  
Oncology Unit  
Institut Bergonie,  
Bordeaux, France



# ORGANIZATION – COMMITTEES

## Organized by



2nd Department of Obstetrics and Gynecology  
Medical School, Aristotle University of Thessaloniki  
Hippokration General Hospital, Thessaloniki, Greece  
Head of Department: Associate Professor Konstantinos D. Dinas

## In Affiliation with



- Institute of Gynecologic Oncology & Senology, Thessaloniki, Greece



- Institut Bergonie, Bordeaux, France

## Organizing Committee

### Presidents:

Konstantinos Dinas, Frederic Guyon,  
Alexios Papanikolaou

### Scientific and Organizing Moderator:

Stamatios Petousis

### Vice President:

Alexandros Sotiriadis

### General Secretary:

Angelos Daniilidis

### Members:

S. Angelidou  
E. Athanasiou  
A. Anastasiou  
F. Carcea  
A. Floquet  
K. Katsanoulas  
E. Katsiki  
E. Katsika  
A. Liberis  
C. Margioulas-Siarkou  
K. Mponiou  
M. Mixiou  
E. Mouloudi  
M. Nasioutziki  
P. Papakotoulas  
K. Pantazis  
N. Papoutsopoulos  
G. Prtilas  
V. Sardaridou  
A. Sioutas  
N. Tsabazis  
E. Vavoulidis

## Scientific Committee

### Presidents:

Evangelos Paraskevaidis - George Mavromatidis

### Members:

R. Manchanda  
A. Rodolakis  
A. Daponte  
G. Grimpizis  
A. Loufopoulos  
G. Androutsopoulos  
D. Chaidopoulos  
I. Kalogiannidis  
E. Kontomanolis  
T. Theodoridis  
D. Tsolakidis  
L. Zepeiridis  
F. Chatzinikolaou  
A. Basonidis  
P. Chatzis  
V. Moschaki  
E. Mouloudi  
E. Katsiki  
K. Katsanoulas  
E. Katsika  
S. Manoloudi  
Z. Razumova  
A. Sarti  
O. Theodoropoulou

# GENERAL INFORMATION

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

### Webinar Date

Saturday, 27th March 2021

### Endorsements



European Society of Gynaecologic Oncology (ESGO)



French Society of Gynaecological Oncology (SFOG)

### Certificate of Attendance

Attendance certificates will be sent to those who attend the Webinar, by the Secretariat of the Webinar

### Official Language

The official language of the Webinar is English

### Webinar Organization Office



VOYAGER TRAVEL & CONGRESS  
Vas. Irakleiou 26, 546 24, Thessaloniki, Greece  
e-mail: [congress-secretary@voyagertravel.gr](mailto:congress-secretary@voyagertravel.gr)  
website: [www.voyagertravel.gr](http://www.voyagertravel.gr)

# SPEAKERS

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

### **Androutsopoulos Georgios**

Assistant Professor of Obstetrics & Gynaecology, Head of Gynaecological Oncology Unit, Department of Obstetrics & Gynaecology, School of Medicine, University of Patras, Greece

### **Angelidou Stamatia**

Consultant Pathologist, Department of Pathology, Hippokration General Hospital, Greece

### **Boniou Konstantina**

Radiation Therapist - Oncologist, Radiation Therapy Oncology Department, Theagenio Hospital Thessaloniki, Greece

### **Chaidopoulos Dimitrios**

Associate Professor of Gynecologic Oncology, Medical School, University of Athens, Oncology Department, Alexandra General Hospital, Greece

### **Coriolan Lebreton**

Medical Oncologist, Oncology Unit Institut Bergonie, Bordeaux, France

### **Daniilidis Angelos**

Assistant Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 2nd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Daponte Alexandros**

Professor of Obstetrics and Gynecology, Medical School, University of Thessaly, Head of the Obstetrics and Gynecology Department, University General Hospital of Larissa, Greece

### **Dinas Konstantinos**

Associate Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Head of the 2nd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Floquet Anne**

Medical Oncologist, Oncology Unit Institut Bergonie, Bordeaux, France

### **Gekiere Jean-Pierre**

Consultant Anaesthesiologist, Institut Bergonié, Bordeaux, France

### **Guyon Frederic**

President of SFOG, Head of Gynaecologic Oncology Unit Institut Bergonie, Bordeaux, France

### **Kalogiannidis Ioannis**

Assistant Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 3rd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Katsanoulas Konstantinos**

Anaesthesiologist, Clinical Director, Anaesthesiology Department, Hippokrateion General Hospital Thessaloniki, Greece

### **Katsika Eleni**

Anaesthesiologist, Director, Anaesthesiological Department, Hippokration General Hospital, Greece

### **Kontomanolis Emmanouil**

Associate Professor of Obstetrics and Gynecology, Medical School, University of Alexandroupolis, Department of Obstetrics and Gynecology, General University Hospital of Alexandroupolis, Greece

### **Liberis Anastasios**

Obstetrician – Gynecologist, Academic Fellow, 2nd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Margioulas-Siarkou Chrysoula**

Obstetrician – Gynaecologist, 2nd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Mavromatidis Georgios**

Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 2 Department of and Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Papakotolouas Pavlos**

Oncologist, Head of the 1st Pathological Oncology Department, Theagenio Hospital Thessaloniki, Greece

### **Papanikolaou Alexios**

Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 2 Department of and Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Paraskevaidis Evangelos**

Professor of Obstetrics and Gynecology, Ioannina Medical School, Greece, President of Hellenic Society of Colposcopy & Cervical Pathology, President of Hellenic Cervical Pathology Academic Studies Group (HeCPA Group)

### **Petousis Stamatios**

Obstetrician – Gynaecologist, Academic Fellow, 2nd Department of Obstetrics and Gynecology, Hippokration General Hospital, Greece

### **Ranjit Manchanda**

Professor of Gynaecological Oncology & Consultant Gynaecological Oncologist, Department of Gynaecological Oncology | Barts Health NHS, UK

### **Razumova Zoia**

MD, PhD Researcher, Department of Women's and Children's Health, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden

### **Rodolakis Alexandros**

Professor of Obstetrics and Gynecology - Gynecologic Oncology, Head of the 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, Greece

### **Sioutas Angelos**

Obstetrician – Gynaecological Surgeon, exHead of the Department of Obstetrics and Gynecology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Greece

### **Timotheadou Eleni**

Associate Professor in Medicine & Oncology, Medical School, Aristotle University of Thessaloniki, Department of Medical Oncology, Papageorgiou General Hospital, Greece

### **Tsolakidis Dimitrios**

Assistant Professor of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 3rd Department of Obstetrics and Gynecology, Papageorgiou General Hospital, Greece

### **Vaikos Dimitrios**

Anesthesiologist, 424 General Military Hospital of Thessaloniki, 4th Surgery Clinic, Interbalkan Medical Center of Thessaloniki - Athens Medical Group (AMG), Greece



# PROGRAM

**27 MARCH 2021**

**GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19**

**PRESIDENTS OF SEMINAR:** Konstantinos Dinas, Alexios Papanikolaou, Frederic Guyon  
**ORGANIZING MODERATOR:** Stamatios Petousis

## **08:30-10:00 Round Table 1. Conservative management of gynaecological cancer**

**Presidents:** Alexios Papanikolaou, Pavlos Papakotoulas

1. *Conservative management of endometrial cancer. When, how, to whom?*

**Anastasios Liberis**

2. *Cervical cancer: could chemoradiotherapy replace all surgical treatment?*

**Konstantina Boniou**

3. *Ovarian cancer: could neoadjuvant chemotherapy replace surgery?*

**Anne Floquet - Coriolan Lebreton**

4. *Chemotherapy in gynaecological cancer: special considerations in the context of COVID-pandemic*

**Eleni Timotheadou**

Commentary: **Dimitrios Tsolakidis, George Androutsopoulos**

## **10:00-11:45 Round Table 2. Minimizing surgical radicality**

**Presidents:** Alexandros Rodolakis, Evangelos Paraskevaidis

1. *When is lymphadenectomy essential in endometrial cancer surgery?*

**Stamatios Petousis**

2. *Laparoscopic sentinel node in endometrial cancer to reduce surgical morbidity: always, sometimes or never?*

**Angelos Daniilidis**

3. *Simple hysterectomy instead of radical hysterectomy for early-stage cervical cancer. Does it indeed compromise outcome?*

**Alexios Papanikolaou**

4. *Avoiding unnecessary surgical treatment of cervical intraepithelial neoplasia. Why and how?*

**Evangelos Paraskevaidis**

5. *Minimally invasive treatment of ovarian cancer: is indeed feasible?*

**Frederic Guyon**

Commentary: **Ioannis Kalogiannidis, Dimitrios Chaidopoulos, Emmanouil Kontomanolis**

## **11:45-12:00 Break**

# PROGRAM

**27 MARCH 2021**

**GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19**

## **12:00-12:30 PLENNARY SESSION 1**

**President: Frederic Guyon**

COVID-19 era. Has it indeed alter our surgical approach?

**Professor Ranjit Manchanda**

## **12:30-13:00 PLENNARY SESSION 2**

**President: Konstantinos Dinas**

Robotic surgery in the treatment of gynaecological cancer during COVID-19 pandemic.  
What is the added value?

**Dr. Angelos Sioutas**

## **13:00-13:45 Round Table 3. Optimizing protocols of postoperative treatment**

**Presidents: Alexandros Daponte, Eleni Katsika**

1. *Lack of Intensive Care Unit availability. How should this change surgical treatment?*

**Dimitris Vaikos**

2. *Sarcopeny as modifiable risk factor for ovarian cancer patients. Time to establish as standard care?*

**Chrysoula Margioulas-Siarkou, Jean-Pierre Gekiere**

Commentary: **George Mavromatidis, Konstantinos Katsanoulas**

## **13:45-14:00 Break**

# PROGRAM

**27 MARCH 2021**

**GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19**

## **14:00-14:30 PLENARY SESSION 3**

Acquiring ESGO accreditation for 2nd Department of Obstetrics and Gynaecology. The trip to the dream

**Konstantinos Dinas**

## **14:30-14:45 PLENARY SESSION 4**

The Importance of Adapting Activities to the Pandemic Reality: the ENYGO Experience

**Zoia Razumova**


## **14:45-15:00 Round Table 4. Multidisciplinary Tumour Board: presentation and live discussion**

**Presentation: Chrysoula Margioulas-Siarkou**

Oncological council: **Alexios Papanikolaou, Konstantinos Dinas, Frederic Guyon, Angelos Sioutas, Stamatios Petousis, Anastasios Liberis, Pavlos Papakotoulas, Konstantina Mponiou, Stamatia Angelidou**

## **15:00-15:30 CLOSING REMARKS**

**Konstantinos Dinas, Alexios Papanikolaou, Stamatios Petousis, Frederic Guyon**



### A

Androutsopoulos Georgios.....9  
Angelidou Stamatia.....11

### B

Boniou Konstantina.....9, 11

### C

Chaidopoulos Dimitrios.....9  
Coriolan Lebreton.....9

### D

Daniilidis Angelos.....9  
Daponte Alexandros.....10  
Dinas Konstantinos.....10,11

### F

Floquet Anne.....9

### G

Gekiere Jean-Pierre.....10  
Guyon Frederic.....9,10, 11

### K

Kalogiannidis Ioannis.....9  
Katsanoulas Konstantinos.....10  
Katsika Eleni.....10  
Kontomanolis Emmanouil.....9

### L

Liberis Anastasios.....9, 11

### M

Margioulas-Siarkou Chrysoula.....10, 11  
Mavromatidis Georgios.....10

### P

Papakotolouas Pavlos.....9, 11  
Papanikolaou Alexios.....9, 11  
Paraskevaidis Evangelos.....9  
Petousis Stamatis.....9, 11

### R

Ranjit Manchanda.....10  
Razumova Zoia.....11  
Rodolakis Alexandros.....9

### S

Sioutas Angelos.....10, 11

### T

Timotheadou Eleni.....9  
Tsolakidis Dimitrios.....9


### V

Vaikos Dimitrios.....10

# SPONSORS

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19

The organizing committee would like to thank the following companies for their support (alphabetical order):



# NOTES

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19



A series of horizontal lines for taking notes, overlaid on a background illustration of a woman's profile with a neural network overlay.



# NOTES

## GYNAECOLOGIC ONCOLOGY TREATMENT IN THE ERA OF COVID-19





GYNAECOLOGIC  
ONCOLOGY TREATMENT  
IN THE ERA OF COVID-19